Published Date: 17 Feb 2023
Researchers at the University of East Anglia are on the verge of developing a new generation of cancer treatment. The futuristic sound treatment will work by turning on the light in the nearby LED.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Herpes virus-based vaccine shows promise in targeting tumors without side effects
2.
Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.
3.
a brand-new generic therapy for different types of cancer.
4.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
5.
If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
The Surprising Role of Magnesium in Digestion, Sleep and Mental Health
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation